KNSA Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- 47.62
- PEG ratio
- —
- P/B
- 6.64
- P/S (TTM)
- 5.53
- EV/EBITDA
- 37.57
Profitability & growth
- ROE (TTM)
- 13.7%
- Operating margin
- 13.7%
- Revenue growth YoY
- 55.5%
- Dividend yield
- —
- Beta
- 0.12
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Kiniksa Pharmaceuticals Ltd
Company profileKiniksa Pharmaceuticals Ltd. (KNSA) is a pioneering biopharmaceutical company dedicated to addressing significant unmet medical needs through the development of novel therapies. Its lead candidate, KPL-404, is a monoclonal antibody specifically engineered to modulate immune responses, showcasing its potential in treating various autoimmune disorders. With a robust clinical pipeline and strategic partnerships bolstering its research and development efforts, Kiniksa is positioned for sustained growth in the competitive biopharmaceutical landscape. The company's steadfast commitment to…
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 105 PICCADILLY, LONDON, UNITED KINGDOM
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
